September 17, 2012 / 7:07 PM / 5 years ago

Gilead's HIV pill could be market leader in 3-5 years: J.P. Morgan

(Reuters) - J.P. Morgan Securities raised its price target on Gilead Sciences Inc to $75 from $70, saying the company's HIV pill could emerge as a "market leader" in three to five years, sending the drugmaker's shares to a life-high.

U.S. health regulators approved the four-drug combination pill, Stribild, on August 27.

Physicians said there were no major concerns with Stribild or with its cost, the brokerage said after a survey of 52 HIV specialists.

Analyst Geoff Meacham, who reiterated his "overweight" rating on the stock, expects Stribild sales of about $2.9 billion in 2015, ahead of Wall Street consensus of $1.5 billion.

Gilead shares, which have risen 8 percent since the approval of the HIV pill, were up 6 percent at $65.68 on the Nasdaq on Monday. More than 16 million shares changed hands by 1454 ET, about 2.5 times their 10-day moving average volume.

Reporting by Adithya Venkatesan in Bangalore; Editing by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below